Strategies to Accelerate the Development of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...
Continue ReadingKnowledge Library
ADC Development: Preclinical Pharmacology Essentials
Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
Continue Reading
Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs
Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...
Continue Reading
Development of Novel ADC-Resistant Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading
AACR 2025 Posters: Sneak Peek
From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...
Continue Reading
Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...
Continue Reading
Developing Resistant Models to Diverse ADC Drugs
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading
Targeting FAK Improves the Tumor Uptake of ADCs
Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...
Continue Reading
Strategies to Accelerate the Development of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges...
Continue Reading